Research Article
Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Table 1
Baseline characteristics.
| | Characteristic | Imatinib + BSC
() | BSC alone
( | P value† |
| | Age (years) | | | | | Median (range) | 54.5 (48–7) | 62.5 (41–73) | — | | Sex | | | | | Male | 8 | 8 | 0.701 | | Female | 6 | 4 | | ECOG PS | | | | | 1 | 8 | 4 | 0.220 | | 2 | 6 | 5 | | 3 | 0 | 1 | | 4 | 0 | 2 | | Change in PS* | | | | | Better | 1 | 0 | 0.003 | | Worse | 1 | 8 | | No change | 12 | 4 | | Primary site of cancer | | | | | Stomach | 5 | 3 | 0.913 | | Small intestine | 7 | 7 | | Rectum | 1 | 1 | | Other | 1 | 1 | | Metastatic sites | | | | | Liver | 5 | 8 | 0.728 | | Peritoneum | 9 | 9 | | Other | 3 | 2 | | Duration of initial treatment with imatinib, months | | | | | Median (range) | 41 (20–79) | 19.5 (1–49) | — | | Best response to initial treatment with imatinib | | | | | CR | 3 | 4 | 0.351 | | PR | 3 | 2 | | SD | 1 | 2 | | PD | 3 | 4 | | NE | 4 | 0 | | Reason for cessation of initial imatinib treatment | | | | | Resistance | 14 | 11 | 0.462 | | Intolerance | 0 | 1 | | Duration of sunitinib therapy, months | | | | | Median (range) | 7.5 (3–17) | 6 (1–34) | — |
|
|
BSC: best supportive care; ECOG PS: Eastern Cooperative Oncology Group Performance Status; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluable.
*Compared with presunitinib status.
†Fisher’s exact test.
|
